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Abstract
Background: The cancer stem cell (CSC) hypothesis proposes that a population of tumor cells bearing stem cell 
properties is responsible for the origin and maintenance of tumors. Normal and cancer stem cells possess the ability to 
grow in vitro as self-renewing spheres, but the molecular basis of this phenotype remains largely unknown. We 
intended to establish a comprehensive culture system to grow prostatospheres (PSs) from both cancer cell lines and 
patient tumors. We then used gene expression microarrays to gain insight on the molecular pathways that sustain the 
PS tumor initiating cell (TIC) phenotype.
Results: Traditional stem cell medium (SCM) supplemented with Knockout™SR (KO) allows the propagation of 
monoclonal PSs from cell lines and primary cells. PSs display gene expression and tumorigenicity hallmarks of TICs. 
Gene expression analysis defined a gene signature composed of 66 genes that characterize LNCaP and patient PSs. 
This set includes novel prostate TIC growth factors (NRP1, GDF1, JAG1), proteins implicated in cell adhesion and 
cytoskeletal maintenance, transcriptional regulators (MYCBP, MYBL1, ID1, ID3, FOS, ELF3, ELF4, KLF2, KLF5) and factors 
involved in protein biosynthesis and metabolism. Meta-analysis in Oncomine reveals that some of these genes 
correlate with prostate cancer status and/or progression. Reporter genes and inhibitors indicate that the Notch 
pathway contributes to prostatosphere growth.
Conclusions: We have developed a model for the culture of PSs, and provide a genomic profile that support CSCs 
identity. This signature identifies novel markers and pathways that are predicted to correlate with prostate cancer 
evolution.
Background
There is overwhelming evidence supporting the concept
that only a specific group of cells, among the cellular het-
erogeneity of a tumor, possesses self-renewal and multi-
lineage differentiation potential and is, therefore,
responsible for tumor development[1]. These cells, so
called "tumor initiating cells" (TICs) or "cancer stem cells"
(CSCs), have been documented in most circulating and
solid tumors as well as in numerous established cancer
cell lines[2]. The expression of adult stem cell surface
markers (e.g. CD133, CD44, ESA) as well as the expres-
sion of specific embryonic stem cell genes (e.g. OCT3/4,
NANOG, SOX2) is one of the hallmarks of the TIC [2].
TICs also display increased potential for anchorage-inde-
pendent growth, capacity to form spheroids in vitro, and
propensity to undergo epithelial-mesenchymal transition.
Nevertheless, in the current paradigm, the gold standard
property of a TIC is its ability to initiate and generate a
tumor in immunodeficient mice. Due to their properties,
tumor initiating cells are thought to be responsible for
cancer chemo-resistance and relapse, and thus they rep-
resent a significant concern for cancer prognosis and
therapy[1].
The isolation of TICs is based on the expression of spe-
cific cell surface markers, the ability to pump out Hoechst
dye (referred as "side population" or the cells that do not
retain the dye), the high aldehyde dehydrogenase 1 activ-
ity or the ability to grow in vitro as unattached spheroids
in an appropriate medium [2]. Furthermore, we and oth-
ers have recently proposed that invasion ability could be
also used for the enrichment of TICs [3,4]. The isolation
of neural stem cells and the propagation of "neuro-
spheres" was the first breakout in the culture of adult
stem cells [5]. Neurospheres are relatively undifferenti-
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ated stem cell clones and mounting data have validated
their use as a self-renewal model. Using neurosphere cul-
ture strategies, unattached clusters of cells with TIC
properties, called 'prostatospheres' (PS), have been grown
from both malignant and non-malignant prostate tissue
[6]. The isolation and culture of TICs as PSs represents a
convenient model for their study, since we currently lack
universal TIC surface markers, and because it allows the
propagation of TICs in their undifferentiated state. How-
ever, it remains to be determined to what extent sphere
culture selectively enriches for TICs. Likewise, the
molecular and cellular basis of PS growth, as well as it rel-
evance for TIC biology, have not been analyzed in depth.
Various signaling pathways, including Wnt, Notch, Hh
and PI3K/AKT, have been associated with TICs [7]. Most
of these pathways have previously been found to be active
in both embryonic and cancer cells. In particular, canoni-
cal Notch pathway activation has been reported in nor-
mal adult stem cells [8,9] and malignancies [10,11], and
has recently been connected to self-renewal of TICs [12].
Notch signaling starts with a direct interaction between
cell surface ligands and Notch membrane receptor, fol-
lowed by cleavage of the Notch intracellular domain
(NICD) and its translocation to the nucleus where it
interacts with CSL/RBPJ transcription factor and triggers
the transcription of Notch target genes [12]. In addition,
Notch signaling is relevant in prostate gland develop-
ment, neoplasia and possible for prostate TICs [11].
Here we show that stem cell medium (SCM) supple-
mented with Knockout™SR serum replacement (KO) pro-
motes the growth and serial passage of clonally derived
PSs. This culture method is suitable not only for estab-
lished cell lines but also for prostate cancer stem cell pri-
mary cultures (PCSC-1, PCSC-2 and PCSC-3, referred to
as group as "PCSCs"), providing a valuable model for the
integrated study of patient and cell line material. The TIC
nature of PSs is supported by their increased tumorige-
n i c i t y  i n  m o u s e  x e n o g r a f t  s t u d i e s ,  a s  w e l l  a s  b y  t h e i r
increased expression of several established stem cell
markers.
In the search for the molecular basis of PS growth we
performed genome expression studies using microarrays.
We found that the promoters of the genes modulated in
PSs are enriched in binding sites for known TIC tran-
scription factors, such as c-Myc and TCF3, thereby rein-
forcing their TIC nature. We also identified 66 PS
regulated genes that are common to LNCaP and PCSCs,
and highlighted interesting molecules that have recog-
nized roles in developmental processes, tissue remodel-
ing, cell invasion and stem cell niche. Meta-analysis in
Oncomine prostate datasets indicates that 32 of the 66
genes in this signature correlate with prostate cancer sta-
tus. These genes could, therefore, represent prostate CSC
markers that have still uninvestigated roles in TIC biol-
ogy.
Finally, the overexpression of Jag1 in the PS signature,
lead us to study the contribution of the Notch pathway to
PS biology. We uncovered an overexpression of several
Notch signaling genes, an increase in CSL/RBPJ activity
in PSs, as well as a reduction of sphere formation as a
result of gamma secretase inhibition. This evidence sup-
ports a role for the Notch pathway in PS maintenance. In
conclusion, our findings support the use of PS cultures in
SCM-1%KO as a model for TIC propagation and isolation
that unifies cell lines and primary culture systems, and
exposes new molecular actors that might be relevant for
TIC biology and prostate cancer progression.
Results
SCM-1%KO supports monoclonal PS growth from 
CD44+CD24-TICs and the total cell line
Critical to the study of the TIC populations within
tumors is the establishment of cultureconditions that
allow putative TICs to exhibit symmetric (self-renewal)
and asymmetric (differentiation) cell divisions. In order
to find a comprehensive medium for the growth and
maintenance of prostate TICs, we tested the ability of
various media and serum replacements developed for
embryonic and mesenchymal stem cell research, to sup-
port PS growth (data not shown). W e found that SCM
supplemented with 1% KO, promoted the formation of
spheres in LNCaP as well as other prostate cell lines (data
not show). In order to determine whether the PS initiat-
ing cells represent the previously characterized TICs iso-
lated by surface markers [13], LNCaP CD44+24-stem cell
population was sorted and cultured in sphere forming
conditions. As shown in Figure 1A, depleted LNCaP cells
(previously shown to represent the differentiated non-
TIC subpopulation) attach to the flask as a monolayer
whereas CD44+24-cells grow as spheres in SCM. Addi-
tion of 1% KO supplement causes an increase in the pro-
liferation rate of the CD44+24-spheres, as indicated by
the augmented diameter of the spheres.
When the bulk LNCaP cell line was cultured in SCM-
1%KO medium, we observed the growth of spheres mor-
phologically similar to those originating from the
CD44+CD24-subpopulation (Figure 1A, "total"). After
day 7, the cultures displayed a mixed population of adher-
ent cells similar to those grown in RPMI-1640-10% FBS,
and PSs (approximately 30%) (Figure 1B). Indeed, PSs
could be serially passaged without a decrease in the per-
centage of sphere forming cells, which denotes the pres-
ervation of their self-renewal potential. qRT-PCR analysis
of some stem cell genes (CD44, Oct3/4 and Nanog) indi-
cated maintenance of their expression along at least eight
generations (data not shown). Therefore, this cultureDuhagon et al. BMC Genomics 2010, 11:324
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condition seems to allow for the enrichment in TIC
spheres from the total LNCaP cell line.
In order to distinguish between cell aggregation and
clonal origin of these PSs, we carried out cell tracing
experiments. Single cell suspensions were stained with
two different dyes in separate reactions and then mixed in
equivalent amounts and cultured in SCM-1%KO for 7
days. Following cell up-take, these two dyes become cova-
lently linked to thiol groups in the cytosol and segregate
with the cytoplasm. At day 7, the vast majority of the
spheres have only one type of fluorescence, indicating
that they have a single cell origin (Figure 1C). Two-col-
ored spheres probably arose from peripheral adhesion of
small strongly-stained dead cells. This experiment dem-
onstrates that our culture conditions promote the clonal
growth of prostatospheres.
SCM-1%KO supports monoclonal PS growth from 
CD133+TICs isolated from primary cultures
Subsequently, we performed a similar study with three
primary prostate cancer stem cells isolated from recur-
rent prostate tumors of 55-, 56- and 70-year old patients
that underwent chemotherapy and radiation therapy
prior to tumor extraction. Thereafter, the tumor cells
were disaggregated and TIC were sorted for expression of
the adult stem cell marker PROMININ1 (CD133) (per-
sonal communication, Jay Sharma). All three PCSCs grow
as epithelial monolayers in the commercial media,
express the TIC markers CD44, CD133, NANOG,
Figure 1 Prostatosphere formation in LNCaP cell line. A. Morphology of LNCaP subpopulations plated in SCM only (-) or in SCM-1%KO (1%KO). 
Top: 2400 dpi scans. Bottom: 20 × lens phase contrast images.
B. Percentage (%) of sphere forming cells during 6 serial passages or generations (G 1-6).
C. Fluorescent microscopy images of Cell-tracing experiments with 20 × objective.
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OCT3/4, BMI1 and exhibit ALDH activity (Additional
file 1A) and anchorage independent growth (Additional
file 1B). Additionally, they are highly tumorigenic in
NOD/SCID mice, with 100 cells producing tumors in all
animals in less than eight weeks (Additional file 1C).
These properties are consistent with PCSCs containing a
TIC subpopulation.
The three primary cell cultures also form spheres when
cultured in SCM-1%KO (Figure 2A). Although the pro-
portion of stem cell markers and the anchorage indepen-
dent growth (Additional file 1) correlate with
tumorigenicity, the similarity in sphere forming capacity
suggests that it correlates to a lesser extent. Cell tracing
experiments demonstrated that PCSC's PSs are also
monoclonal (Figure 2B). All three PCSC were passaged
weekly for more that 12 generations (Figure 2C). As
shown in Figure 2D PCSCs gained sphere-forming capac-
ity along the generations. Furthermore, several stem cell
markers were shown to be progressively up-regulated
along consecutive passages. This data indicate that SCM-
1%KO medium not only sustains the growth of primary
PCSCs but also positively selects for TICs during pas-
sages.
PSs are more tumorigenic than the parental cell lines
In order to determine if PSs grown in SCM-1%KO have
increased tumorigenic ability, as it would be expected for
TICs, we compared the tumorigenicity of the PSs and the
parental cultures. LNCaP PSs grown in SCM-1%KO for
one week generate palpable tumors in NOD/SCID mice
in approximately four weeks in 5/5 animals (Figure 3).
That is seven times faster than what was reported by our
group before [13]. Likewise, purified PCSC PSs grown for
one week in SCM-1%KO have an increased ability to
form tumors than their parental counterparts (Figure 3).
This difference in tumorigenicity seems to be indirectly
proportional to tumorigenicity and stem cell marker
expression of the parental cell lines. For instance, PCSC-3
parental culture is the least aggressive in mice (Additional
file 1C) and the one that has the lowest expression of TIC
markers (Additional file 1A). Simultaneously, it shows the
largest difference in tumorigenicity between PSs and
parental cell culture (Figure 3) as well as the fastest
increase in stem cell gene expression (Figure 2D), sug-
gesting that it undergoes a strong selection for TICs in
this culture condition. Likewise, the PCSC-1 phenotype
indicates the highest TIC content (Additional file 1), but
no difference in tumorigenicity between adherent cul-
tures and the PSs (Figure 3). In that case, a reduction in
the number of injected cells would likely be necessary to
detect enrichment in TIC in the PSs.
In summary, the mice xenograft experiments demon-
strate that PS culture enriches in TICs both in LNCaP as
well as in PCSCs.
Gene expression analysis of prostatospheres and 
differentiated cells
The discovery of the molecular pathways that are
required for the maintenance of self-renewing TICs may
ultimately lead to targeted therapies against this unique
population of tumor cells. In order to identify the molec-
ular basis of PS biology, we carried out whole genome
gene expression analysis using microarrays. Microarray
data were deposited in GEO (LNCaP expression data in
GSE19704 and PCSCs expression data in GSE19713).
Gene expression profiles of prostatospheres growing in
SCM-1%KO for 7 days were compared to the parental cell
line growing in the commercial medium containing 10%
FBS.
Several genes that were previously reported to be
related to TIC maintenance were found to be up-regu-
lated in SCM-1%KO cultured PSs (Figure 4A). Microar-
ray analysis shows that CDH1, PROM2 and ITGB1 are
upregulated in both LNCaP and PCSCs. Although not
detected by microarrays, further qRT-PCR assessment
also showed that NES and NANOG are significantly
upregulated in both (Additional file 1). AR is downregu-
lated in the PSs derived from the androgen-dependant/
sensitive LNCaP cell line. For PCSCs, the AR protein was
undetectable by western blots although expression of AR
mRNA was measurable by qRT-PCR (data not shown).
Due to previously published reports on PROM2 and
SOX9 expression in prostate progenitor cell [14,15] we
also addressed their gene expression levels (Figure 4). The
changes in stem cell markers identified by microarray
were further confirmed by qRT-PCR (Additional file 2A
for LNCaP and 2B for PCSCs). Therefore, our gene
expression study confirms that PSs preferentially express
already described, as well as potentially novel, TIC genes.
Due to the enormous interest in the use of well estab-
lished cell lines as model systems for cancer stem cell
research, we sought to find the commonalities between
LNCaP PSs and the primary prostate cultures by gene
expression analysis. We found a total of 845 genes simi-
larly and significantly (≥1.8-fold change and p ≤ 0.05)
modulated in all three PCSCs and 1454 in LNCaP PS.
Among these, only 66 were regulated in the same direc-
tion in both the PCSCs and LNCaP gene lists. In Table 1,
the genes are classified according to their function and
the average fold-change observed in PCSCs and LNCaP is
also shown. In order to confirm the microarray data, four
genes were assessed by qRT-PCR (Additional file 2C).
Although changes in the abundance of individual mRNAs
may explain a particular biological situation, the con-
certed action of a group of genes is a more robust means
to understand the molecular processes and regulators
that drive a given phenotype [16]. Core Analysis of the 66
gene signature in Ingenuity Pathways Analysis (IPA,
http://www.ingenuity.com) yielded Cell Death and Cellu-Duhagon et al. BMC Genomics 2010, 11:324
http://www.biomedcentral.com/1471-2164/11/324
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Figure 2 Prostatosphere formation in PCSCs cell lines. A. Morphology of PCSC subpopulations plated in SCM only (-) or in SCM-1%KO (1%KO). Top: 
96 well plate well 2400 dpi scans, Bottom: 20 × lens phase contrast images.
B. Fluorescent microscopy images of Cell-tracing experiments. 20 × lens magnification.
C. Percentage (%) of sphere forming cells during 12 serial passages or generations (G 2-12).
D. qRT-PCR of stem cell genes along generations. OCT3/4, NANOG, BMI1, CD44, CD133, TP63, K14 mRNA levels were assessed and only those that 
displayed variation along the generations are shown. In order to integrate the data into a single plot, the expression is presented as percentage of the 
maximum observed fold change. Rightmost tables indicate the absolute fold-change per gene and cell line.
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lar Movement as the two top categories (p ≤ E-07), fol-
lowed by Cancer and Reproductive system Disease (p ≤
E-06) (Additional file 3). In addition, most of the tissue
specific categories found in this analysis represent meso-
dermal derived tissues (connective, cardiovascular, lym-
phoid, gastro-intestinal) (Additional file 3).
In order to predict which transcription factors might be
responsible for the maintenance of the spheroid state, we
used the Molecular Signatures Database (MSigDB, http://
www.broadinstitute.org/gsea/msigdb/index.jsp) to search
overrepresentation of transcription factor binding sites in
the promoters of the PS genes modulated ≥2-fold at p ≤
0.01 (473 genes of PCSCs and 443 in LNCaP). Of the five
common TF predictions (Additional file 4), MYC and
TCF3/E2A, MYOD and YY1 are well known somatic
stem cell transcription factors, whereas the function of
REPIN1 is still unknown. Canonical Wnt pathway tran-
scriptional regulators (as Tcf1, Lef1, Tcf8) and other MYC
associated TFs (as MAZ) were also found to be overrep-
resented in the promoter regions of the specific PS data-
sets (Additional file 4).
Meta-analysis for Correlations of PS genes and prostate 
cancer status and progression
Since TICs are proposed to be fundamental for tumor
maintenance, invasion, metastasis and drug resistance,
we investigated if the 66 PS genes were correlated to
prostate cancer status or progression using the Oncom-
ine database analysis tool [17-20]. We interrogated the 66
gene list in all prostate cancer studies available in
Oncomine. Interestingly, 32 out of the 66 genes are corre-
lated with prostate cancer in at least one prostate cancer
profiling study (Figure 5). Furthermore, the vast majority
of these genes associate with prostate cancer in more
than one study, which reinforces their putative signifi-
cance for this disease. TMP1 and GALNT3 display the
most significant correlation among the list, as indicated
by the intensity of the colors of the corresponding boxes.
Only the downregulated genes correlate with tumor stage
and grade. The finding of these numerous significant cor-
relations with the clinical set underscores the importance
of our PS signature for prostate cancer status and pro-
gression.
Figure 3 Mouse xenograft experiments for determination of tumorigenicity. Male NOD/SCID mice were subcutaneously injected with 100 cells 
from either parental (10% FBS) or sphere cell (SCM-1%KO). Mice were weekly monitored for tumor formation. Kapplan-Meier curves for LNCaP and the 
three PCSC cell lines are presented.
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Notch pathway is upregulated in PSs and may contribute to 
PS maintenance
The significant increase in JAG1 expression observed in
our microarray analysis, and subsequently confirmed by
qRT-PCR (Additional file 2C), together with the well doc-
umented role of the Notch pathway in the maintenance of
"stemness", lead us to study the involvement of this path-
way in SCM-1%KO PS growth and maintenance [12]. Ini-
tially, we queried the microarrays for genes that belong to
the canonical Notch pathway and genes that participate
in its crosstalk with the Wnt and Hh pathways[21]. As
shown in Figure 6A, many of these genes are up-regulated
in LNCaP and PCSCs PSs. Additionally, reporter gene
analysis using the promoter of HES1, whose transcription
is driven by CSL, evidenced a 2-3-fold increase in
reporter activity in LNCaP PSs relative to the parental
cell line (Figure 6B). Co-expression of NICD stimulates
HES1 promoter activity in a similar magnitude thus sup-
porting the specificity and sensitivity of the reporter
assay. Finally, we found that the γ-secretase inhibitor (L-
685,458, Calbiochem) not only inhibited the growth of
LNCaP PSs but also induced an adherent morphological
phenotype (Figure 6C). This data indicate a higher activ-
ity of the Notch pathway in PSs, and a role of this signal-
ing cascade in PS growth.
Discussion
The notion that progenitors as well as TICs can grow in
vitro as spheroids has been extensively documented for
several tissues types. However, the lack of consensus cul-
turing conditions has hampered the elucidation of the
m o l ecu la r  pa t h wa ys  t h a t  s us t a i n  t h is  p h e n o t ype .  I n  a n
attempt to find a comprehensive medium suitable for the
selection and propagation of prostate TICs, we tested
various embryonic stem cell media. We found that SCM
supplemented with Knockout™SR (Gibco-Invitrogen) was
able to select TICs, sustaining the growth of PSs not only
from normal and cancer cell lines, but also from early
passage prostate tumor cell cultures. We demonstrated
that these PSs have a monoclonal origin, a relevant aspect
that is seldom addressed in the cancer stem cell field. The
stem cell identity of these prostatospheres was supported
by their extensive in vitro self-renewal potential in the
"neurosphere assay", the expression of known prostate
TIC markers and the increased tumorigenicity compared
to the parental cell line. Indeed, SCM-1%KO culture
seems to select in favor of TICs along passages, as was
previously observed for normal mouse prostate progeni-
tor cells [22]. It is therefore possible that this culture sys-
tem provides a means for the long-term enrichment of
TICs.
Our analysis of stem cell markers evidenced that PSs
preferentially express some classic embryonic stem cell
(OCT3/4, Nanog) and TIC (TP63, CDH1, ITGB1,
KRT14, KRT5) markers. The down-regulation of AR
mRNA in LNCaP is in agreement with the reported
reduction in AR expression in prostate TICs[22]. Our
data also suggest that prominin-2 could be an interesting
new marker for prostate cancer TICs (Figure 2A).
PROM2 is a paralogue of PROM1 that is expressed in the
prostate and co-localizes with Promin1 in epithelial cells
[23]. Indeed, PROM2 protein is enriched in cells located
in the basal compartment of the glandular epithelium
where only few cells were found to be positive for
PROM1 [14]. Another attractive stem cell marker candi-
date is the HMG-box class transcription factor SOX9,
which is expressed in embryonic and somatic progenitor
cells [24]. Moreover, Sox9 is required for prostate devel-
opment [15] and its expression was found to be restricted
to basal epithelium in the normal human adult [25]. Fur-
thermore, prostate tumors express this TF and its expres-
sion increases in relapsed hormone refractory
tumors[25]. The same report showed that Sox9 is regu-
lated by β-catenin and affects prostate cancer cell prolif-
eration, angiogenesis and invasion; in particular in the
LNCaP cell line. Finally, our data also support the obser-
vation that NANOG is a key regulator of prostate TICs
[26].
In order to interpret our microarray data, we carried
out several analyses. IPA highlighted cell death and cellu-
lar movement as the principal gene categories regulated
in PSs, which is consistent with the modulation of self-
renewal and with the morphological differences between
monolayer and spheroid growth. The finding of an
enrichment in embryonic TFs related to MYC and TCF-
3, which are indeed regulators of cancer stem cell path-
Figure 4 Expression of CSC markers in PSs. Heatmaps of the mRNA 
levels of literature-defined CSC markers in LNCaP and PCSCs. Each 
heatmap compares spheres growing in SCM-1%KO (spheres) and ad-
herent cultures growing in commercial medium supplemented with 
10% FBS (parental). Left panel shows three biological replicates of LN-
CaP cell line. Right panel shows the three individual primary cell cul-
tures from PCSC-1 (1), PCSC-2 (2) and PCSC-3 (3) as indicated, and the 
result is the average of the two replicates for each cell line. Only genes 
that show a significant change (p > 0.05) are included in the heatmap.
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Table 1: List of 66 genes modulated in PSs classified by their function.
FUNCTION Gene Name Symbol PCSC LNCaP
Adhesion Cell-Cell major histocompatibility complex, class II, DM alpha HLA-DMA 2.0 2.2
cadherin 3, type 1, P-cadherin (placental) CDH3 2.1 2.0
HLA complex group 4 HCG4 -1.9 -1.9
activated leukocyte cell adhesion molecule ALCAM -2.3 -2.3
Cell-Matrix Kallmann syndrome 1 sequence KAL1 -2.0 -2.2
Extracellular matrix collagen, type VI, alpha 1 COL6A1 1.8 2.7
Tight junction claudin 3 CLDN3 2.1 1.9
Cell cycle Protein biosynthesis MYC induced nuclear antigen MINA -1.9 -1.9
Regulation cyclin E2 CCNE2 -2.1 -2.7
Cytoskeleton Actin binding tropomyosin 1 (alpha) TPM1 -2.4 -2.1
gelsolin (amyloidosis, Finnish type) GSN 2.1 1.9
Regulation Src homology 3 SGEF -2.4 -2.1
Growth factor Receptor neuropilin 1 NRP1 8.7 2.8
Secreted growth differentiation factor 15 GDF15 8.0 2.2
Metabolism Metals metallothionein 1G MT1G -4.1 -1.9
metallothionein 1H MT1H -4.4 -1.8
metallothionein 2A MT2A -4.8 -1.8
Carbohydrate UDP-N-acteylglucosamine pyrophosphorylase 1 UAP1 -3.1 -2.1
DNA RAD18 homolog (S. cerevisiae) RAD18 -1.9 -1.9
Enzyme methionine sulfoxide reductase B3 MSRB3 -2.1 -2.4
Hormone membrane metallo-endopeptidase MME -3.0 -2.5
Sugar biosynthesis lectin galactoside-binding 8 galectins LGALS8 -2.2 -2.0
mannosidase, alpha, class 1C, member 1 MAN1C1 1.9 1.8
Protein biosynthesis STAM binding protein-like 1 STAMBPL1 -2.0 -2.1
cysteinyl-tRNA synthetase CARS -2.2 -1.9
glycyl-tRNA synthetase GARS -2.2 -2.1
tryptophanyl-tRNA synthetase WARS -2.5 -2.8
heat shock 60 kDa protein 1 (chaperonin) HSPD1 -2.1 -3.4
Protein stability YOD1 OTU deubiquinating enzyme 1 homolog YOD1 -2.0 -2.1
Protein binding tissue factor pathway inhibitor TFPI 2.4 1.8
neuron navigator 3 NAV3 -5.5 -2.3
Signaling Hormone relaxin 2 RLN2 -1.8 -2.0
Hormone Receptor prostaglandin E receptor 4 (subtype EP4) PTGER4 -3.6 -2.9
Integrin sema, immunoglobulin (Ig) and short basic domain SEMA3B 1.9 1.8
Kinase dual specificity phosphatase 6 DUSP6 2.0 2.2
Ligand jagged 1 (Alagille syndrome) JAG1 4.0 3.2
Membrane traffic synaptojanin 2 SYNJ2 -2.0 -2.3
Secreted clusterin CLU 2.8 2.3
amyloid beta (A4) precursor-like protein 2 APLP2 2.7 2.0
c-mer proto-oncogene tyrosine kinase MERTK 2.1 2.0
RIO kinase 3 (yeast) RIOK3 -1.9 -2.2
Transcription Activator c-myc binding protein MYCBP -2.4 -2.4
Activator v-myb myeloblastosis viral oncogene homolog (avian)-like 1 MYBL1 -3.4 -2.0
Inhibitor inhibitor of DNA binding 3 ID3 -6.7 -3.1Duhagon et al. BMC Genomics 2010, 11:324
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ways [27,28], reinforces the TIC identity of the PSs. In
fact, our group and others recently provided evidence in
favor of a role for Wnt signalling in prostate TICs
[13,29,30]. MYOD1 has been recently implicated in myo-
blast maintenance, and, in combination with TCF3, it
inhibits myoblast differentiation leading to Rhabdomyo-
sarcomas [31]. YY1 is a pleiotropic transcription factor
expressed in prostate glandular epithelium and basal
cells, and its expression is positively correlated with pros-
tate cancer metastasis (reviewed in [32]). Indeed, it is well
documented to be involved in specification of mesoder-
mal lineages [32]. The prediction of mesenchymal tran-
scription factor activity (MYOD1 and YY1) could be
indicative of an epithelial-mesenchymal transition, which
has lately been related to tumor progenitor cell plasticity
[4,33]. In summary, the four known TF predicted to be
modulated in PCSCs and LNCaP PSs are known to be
active in adult stem cells.
We also defined a set of 66 genes that are analogously
and significantly regulated in LNCaP and PCSCs (Table
1). It includes several cell adhesion and cytoskeletal pro-
teins, signaling molecules, transcriptional regulators and
metabolic factors. T he role of most of these factors in
TIC biology has not yet been studied. To date, three com-
plete gene expression datasets of putative prostate TICs
have been published. Dubrovska et. al. reported the
genomic profiling of PSs derived from DU145 and PC3
cell lines [34]. Strikingly, 11 genes of our 66 gene signa-
ture (TFPI, NAV3, MYCBP, MSRB3, MERTK,
LOC440731, ID3, ID1, GSN, CCDC50 and C3orf59)
overlap with their dataset. Analysis of CD133+ vs.
Alpha2lowprostate tumor cell array data published by
Birnie et al. reveal a set of four genes common to our sig-
nature (JAG1, APLP2, SEMA1A and RIOK3)[35]. Com-
parison of the gene expression profiles of CD133+ and
CD133- cells isolated from hormone-refractory prostate
cancer biopsies, published by Shepherd et al. [36], shows
that EIF2S1, RAD18, QKI, MAN1C1 and MERTK are sig-
nificantly regulated in the direction observed in our sig-
nature. The small overlap between the studies might be
explained by the differences in the methods used for the
isolation and culturing of TICs.
Remarkably, 31 of the 66 genes correlated to prostate
cancer in our study of Oncomine dataset. Among them,
several have already been reported to be associated with
prostate cancer. Neuropilin1, for instance, has been pro-
p o s e d  a s  a  m a r k e r  o f  a g g r e s s i v e n e s s  o f  p r o s t a t e  c a r c i -
noma, as well as other tumor types [37]. Its ability to
modulate tumor cell invasion and migration represents
one interesting commonality with cancer stem cells [38].
Likewise, GDF15 has been associated with the progres-
sion of diseaseto metastasis [39] and has also been pro-
posed as a prostate cancer biomarker [40]. Its capacity to
inhibit proliferation is consistent with the quiescence of
TICs. In addition, JAG1, one of the ligands for the Notch
receptor, is proposed as a prostate cancer marker [41].
Five other PS up-regulated genes (MERTK13, APLP2 [42],
CLDN 3 [43], DUSP6 [44] and TFPI [45]) have been
found to be overexpressed in prostate cancer and many
other tumor types, but their role in tumor biology is less
Inhibitor inhibitor of DNA binding 1 ID1 -10.2 -5.2
E74-like factor 3 ELF3 2.0 2.5
v-fos FBJ murine osteosarcoma viral oncogene homolog FOS 4.8 2.5
Kruppel-like factor 2 (lung) KLF2 2.1 1.8
CCAAT/enhancer binding protein (C/EBP), gamma CEBPG -1.9 -2.0
E74-like factor 4 (ets domain transcription factor) ELF4 -2.3 -1.9
zinc finger and BTB domain containing 38 ZBTB38 -2.5 -2.0
Kruppel-like factor 5 (intestinal) KLF5 -2.8 -2.0
Translation regulation quaking homolog, KH domain RNA binding (mouse) QKI -2.9 -1.9
eukaryotic translation initiation factor 2, subunit 1 alpha EIF2S1 -1.9 -2.0
Transport Integral Transmembrane channel-like 4 TMC4 1.8 2.2
Zinc solute carrier family 39 (zinc transporter), member 10 SLC39A10 2.3 2.5
solute carrier family 25, member 30 SLC25A30 -1.8 -2.3
solute carrier family 7, member 5 SLC7A5 -2.3 -2.3
Hbc647 mRNA sequence SLC30A1 -12.8 -2.3
Unknown FLJ35024, C3orf59, CCDC113, C5orf35, CCDC50, CCDC76, 
LOC440731
prostatospheres classified by their function.
Table 1: List of 66 genes modulated in PSs classified by their function. (Continued)Duhagon et al. BMC Genomics 2010, 11:324
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Figure 5 Meta-analysis of prostate cancer microarray datasets with PS 66 gene set. Differential activity map of the PS genes that correlate with 
prostate cancer studies in Oncomine microarray database. Columns categorize the different type of studies discriminated by the type of sample from 
which the gene expression data were collected. For instance, "tumor" refers to cancer status comparing normal vs. tumor tissue data, and cancer pro-
gression includes tumor stage or grade. Miscellaneous refers to other types of studies, including primary vs. metastatic, androgen dependence vs. 
independence, recurrence or drug resistance sample groups. Outlier analysis is based on Cancer Outlier Profile Analysis (COPA), which is intended to 
detect gene modulation in a small subset of samples that would not otherwise be detected by the Student's t-test. Red/blue colored boxes represent 
overexpression/underexpression of the indicated gene. Color intensity indicates the statistical significance of the correlation. The color gradient is 
based on the most significant profile within each cell. The number of studies in which the correlation was found is represented by the number inside 
each box.
GENE Tumor Misc.
Tumor 
Stage
Tumor 
Grade
Outlie
rs
NRP1 1
GDF15 6 1
JAG1 1 12
MERTK 1
APLP2 1
ELF3 1 1
TMC4 1 2
GALNT3 2 2
COL6A1 3
CLDN3 2 1
TFPI 3
LOC440731 1
DUSP6 1 2
TPM1 5 5 2 3 3
ZBTB38 1
KLF5 1 1
MYCBP 2
MSRB3 2 3 1 1
LGALS8 2
SLC7A5 1 1
MYBL1 1
MME 3 5
NAV3 1
ID1 2 4
EIF2S1 1 1 1
ELF4 1
KAL1 2 2
MT1G 1 1 2
MT1H 1 1 3
MT2A 1
MYCBP 2
QKI 1 2
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understood. Finally, two genes are associated with non-
prostatic neoplasms: ELF3 with breast cancer [46] and
COL6A1 with astrocytoma [47]. In addition, several of
the 18 down-regulated genes have been previously shown
to be decreased in prostate cancer. Kruppel-like factor 5,
for example, is considered a potential tumor suppressor
in prostate and breast cancer [48] as well as tropomiosin1
in several tumors types [49]. Of note, the tumor suppres-
Figure 6 Notch pathway activity in PSs. A. Heatmap of selected significantly modulated (p ≤ 0.05) Notch pathway genes in LNCaP and PCSCs. Top 
panel shows two biological replicates of LNCaP cell line. Right panel shows the average of the two replicates for each primary cell cultures from PCSC-
1 (1), PCSC-2 (2) and PCSC-3 (3), as indicated.
B. Reporter gene analysis on LNCaP cells transfected with pGL4.17-HES1 (HES1) and pBOS-NCID (NCID). Error bars represent the standard deviation of 
three independent experiments. Y axis shows the relative normalized reporter activity ratio between PS/parental cell line.
C. LNCaP cells cultured for 7 days in SCM-1%KO in the absence (DMSO) or the presence of the indicated concentration of the γ-secretase inhibitor 
(GSI). Representative pictures of each the culture. 20 × lens phase contrast.
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sor candidate ELF4 facilitates entrance to the cell cycle of
quiescent hematopoietic stem cells [50]. Similarly,
expression of the cell adhesion protein KAL1 was found
t o  b e  i n v e r s e l y  c o r r e l a t e d  w i t h  m e t a s t a t i c  c a p a c i t y  i n
prostate and other tumor types [51]. Likewise, several
studies demonstrated a significant negative correlation
between expression of metallothioneins and cancer/pro-
gression in prostate tumors and cell lines [27]. Finally,
MME is contained in a potential prostate cancer suscepti-
bility locus in prostate cancer ACI rat models [52]. Galec-
tins [53], NAV3 [54] and QKI [55] are also correlated to
cancer types other than prostate. Lastly, many genes of
this 66 gene list have not been extensively studied yet.
Contrary to the oncogenic role assigned by the litera-
ture [56,57], our analysis in Oncomine indicates that
SLC7A5 and ID1 are negatively correlated with cancer
progression. The explanation for this discrepancy is
unclear. In support of our findings, ID1 and ID3 down-
regulation has been also observed in another TIC profil-
ing study [34].
Due to the over-expression of the Jag1 Notch1 receptor
in PSs, we addressed the involvement of Notch signaling
in PS growth. Gene expression analysis of Notch signal-
ing cascade, reporter gene studies, and pathway inhibi-
tion experiments presented here indicate a higher activity
of the Notch pathway in PSs as compared to the parental
c e l l  l i n e s .  I n  s u p p o r t  o f  o u r  h y p o t h e s i s ,  B i s s o n  e t  a l .
recently reported that the LNCaP derivative, C4-2B,
which displays about five times higher Notch activity
than original LNCaP cells [58], expresses more stem cell
markers and has higher sphere forming ability than
LNCaP [29]. It is also worth mentioning that some of the
genes overexpressed in PSs (including NRP1 [59], SOX9
[60], ID1[61] and YY1 [62]) are thought to be regulated by
Notch signaling. Altogether this data support the hypoth-
esis that the Notch pathway is contributing to the PS phe-
notype.
Conclusion
We presented the isolation and propagation of monoclo-
nal cancer PSs from several cell lines and early passaged
tumor cells. In agreement with the TIC identity of these
PSs, we demonstrated that they bear the fundamental
TIC traits of marker expression, self-renewal and tumori-
genicity. The culture medium used in our study could
provide a new means for the standardization of prostate
TIC cultures, and may possibly reduce the difficulties of
the comparison between laboratory cell lines and patient
material.
Furthermore, we propose new candidate prostate TIC
markers (PROM2 and SOX9) as well as potential bio-
markers for prostate cancer status and progression that
may be related to the TIC phenotype. Further studies will
be needed to understand the role of each one of them.
Finally, we show evidence in favor of a role of the Notch
pathway in the maintenance of PS phenotype.
Methods
Cell culture
LNCaP lymph node metastatic human prostate carci-
noma cell line was purchased from ATCC (ATCC® Num-
ber CDL-1740™) and cultured following provider's
instructions. LNCaP cells used in our study are late pas-
sages and have been cultured without addition of andro-
gens.
PCSC-1, PCSC-2 and PCSC-3 prostate cancer stem
cells (PCSCs) were purchased from Celprogen®. They
were isolated as primary cells from human adult prostate
cancer tissue based on the expression of the adult stem
cell marker Prominin1 (CD133) (personal communica-
tion, Jay Sharma). The cells were cultured with the
medium, extracellular matrix coated flasks and guidelines
provided by the company.
Prostatosphere culture and assay
In order to obtain prostatospheres from either LNCaP or
PCSCs, exponentially growing cultures were dissociated
to single cells by standard trypsinization, washed three
times with PBS and plated in SCM medium (DMEM:F12
plus 10 ng/mL bFGF, 20 ng/mL EGF, 5 mg/mL insulin,
and 0.4% BSA) supplemented with 1% KO serum replace-
ment (Invitrogen/Gibco, p/n 10828-028) at a density of
2500 cells/mL in tissue culture treated flasks. After
approximately 7 days, the unattached spheres were
removed from the flasks, washed in PBS, incubated in
trypsin and gently pipetted until single cells were
obtained, as determined by microscopic observation.
Trypsin action was immediately inhibited by the addition
of Trypsin neutralizing solution (Lonza Ltd., p/n CC-
5002). Following centrifugation, the cells were resus-
pended at the same density in SCM-1%KO medium.
Seven day old spheres were counted and analyzed using
a GelCount™ automatic plate scanner (Oxford Optronics)
and GelCount Version 0.025.1 software (Oxford Optron-
ics). Plates were scanned at 2400 dpi and the colony
detection algorithm was customized for each cell type
and culture time.
Flow cytometry of LNCaP
Flow cytometric analysis of LNCaP cells was performed
as previously described [13] using antibodies against
CD44 (Caltag human CD44 antibody -PE) and CD24
(Caltag human CD24 antibody -FITC) at 10 μl antibody
per one million cells. Forward and side scatters were used
to select live cells and scatter and pulse width to select
single cells. Control scatters of unstained cells and iso-
type specific stains were used to set the gates. Since the
number of CD44+24-cells obtained in each sorting isDuhagon et al. BMC Genomics 2010, 11:324
http://www.biomedcentral.com/1471-2164/11/324
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extremely low, no assessment of sorting efficiency was
performed.
Gene expression analysis
Total RNA isolation was performed using miRNAeasy
(Qiagen). cDNA was synthesized with SuperScript III
First-Strand Synthesis System for RT-PCR (Invitrogen, p/
n 18080-05) using random hexamers and following man-
ufacturer instructions.
A n a l y s i s  o f  g e n e  e x p r e s s i o n  b y  q R T - P C R  w e r e  p e r -
formed using TaqMan gene expression assays (Applied
Biosystem) in a StepOne Real time PCR machine
(Applied Biosystem) using the comparative Ct procedure.
For the analysis of prostate CSC markers along the gener-
ations, the RNA isolations were carried out with Cell-to-
Ct kit (Applied Biosystem) and the resulting cDNA was
pre-amplifed prior to the qRT-PCR using the TaqMan
PreAmp Master Mix Kit (Applied Biosystem, p/n
4384267) and a pool of stem cell TaqMan Gene Expres-
sion Assays for 10 cycles. 18S RNA was not amplified,
and was used as the RNA content reference control.
For microarray analysis, RNA integrity was assessed
with the Agilent RNA 6000 Nano LabChip Kit (Agilent,
p/n 5067-1511) and only samples with RNA integrity
numbers (RIN) > 9 were used. Ten ug of total RNA from
LNCaP cells were labeled by reverse transcription with
Superscript II (Invitrogen) and oligo-dT in the presence
of Cy3-dUTP for Universal RNA reference control (Uni-
versal Human Reference RNA Stratagene p/n 740000) or
Cy5-dUTP for the samples. Whole Human Genome
Oligo Microarray 4 × 44 K format gene expression arrays
(Agilent, p/n G4112F) were employed for gene expression
studies. The hybridization and washes were performed
using Agilent reagent and protocols (G2534-90001) and
the slides were scanned on a GenePix 4000B scanner
(Molecular Devices, Sunnyvale, CA, USA).
PCSC gene expression wasassessed by Affimetrix U133
arrays (Human Genome U133 Plus 2.0 Array; Affymetrix,
p/n 900467). In this case, 1 ug of RNA was reverse tran-
scribed with T7-oligo(dT) primer and labeled with biotin
using Affymetrix 3' One Cycle Target Labeling kit, fol-
lowing manufacturer's instructions. Three replicates of
each group were prepared, labeled, and hybridized to
Affymetrix human U133 plus 2.0 GeneChip and scanned
on Affymetrix GeneChip scanner 3000. Data were col-
lected using Affymetrix GCOS software.
Statistical and clustering analyses were performed with
Partek Genomics Suite software using RMA normaliza-
tion algorithm for Affymetrix arrays and Loess for Agi-
lent arrays (Partek, Inc.). Differentially expressed genes
were identified with ANOVA analysis of the replicates.
Unless specifically indicated, genes that are up-or down-
regulated more than 2-fold and with a p < 0.01 were con-
sidered. Differentially expressed genes were identified
with ANOVA analysis of the replicates. For statistical
analysis, the three PCSCs were considered as replicates.
Due to the use of different array platforms, the gene lists
were independently generated for LNCaP and PCSCs.
Pathways and signature analysis were also performed in
an independent way for each platform. Commonalities in
Gene Expression changes, modulated pathways and gene
signature matches were obtained as the intersection of
the two independent lists (LNCaP and PCSCs).
Cell tracing analysis
To assess the clonal origin of each prostatosphere, disso-
ciated single cells were stained with the fluorescent dye
CellTracker green or CellTracker red (Molecular Probes/
Invitrogen) at a concentration of 5 μM in separate reac-
tions, following manufacturer instructions. Equal
amounts of the two reactions were immediately mixed
and plated at a density of 2500 viable cells/mL in SCM-
1%KO. Pictures were taken at day 6 using an Olympus
IX70 inverted microscope equipped with a triple 41001
FITC EGFP/BODIPY filter (Ex: HQ480/40, Em: HQ535,
BS: Q505LP).
Mice xenograft for tumorigenicity determinations
NCI-Frederick is accredited by AAALAC International
and follows the Public Health Service Policy for the Care
and Use of Laboratory Animals. Animal Care was pro-
vided in accordance with the procedures outlined in the
'Guide for Care and Use of Laboratory Animals' (Institute
of Laboratory Animal Resources, 1996). Cell cultures
were trypsinized and resuspended in SCM-1%KO at the
indicated cell density. Fifty μl of the suspensions were
combined with 50 μl of BD Matrigel™ Matrix Basement
Membrane (BD Bioscience, p/n 354234) on ice and sub-
cutaneously injected into eight-week old male NOD/
SCID mice (Jackson Labs). Tumor growth was monitored
weekly and dimensions were measured by calipers. Ani-
mals were euthanized and tumors were dissected when
they reached 1.5 sq.mm.
Soft agar assay
Soft agar assays were performed in 96 well plates using
the CytoSelectTM 96-well Cell Transformation Assay
(Soft Agar Colony Formation) kit (Cell Biolabs, Inc., p/n
CBA-130) following manufacturer instructions. Five hun-
dred to five thousand cells per well were used and the
plates were incubated for 10 days at 37°C, 5% CO2. Cells
were stained with Neutral Red (Sigma) for 1 hour,
scanned in a GelCount plate scanner (Oxford Optronics)
at 2400 dpi and analysed using GelCount software.
Meta-analysis for Correlations of PS genes and prostate 
cancer status and progression
For the assessment of correlation between PS gene set
and prostate cancer status and progression we used
Oncomine database analysis tool http://www.oncom-
ine.org developed by Chinnaiyan and colleagues [63]. TheDuhagon et al. BMC Genomics 2010, 11:324
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P-Value Threshold to generate the map was set at 1E-4,
whereas the Outlier Rank Threshold level used to gener-
ate the Outlier column was 50. Student's t-test was used
for analyzing differences between publisheddatasets in
the database.
Transfection and reporter gene assay
For LNCaP reporter gene experiments, cultures growing
in exponential phase were trypsinized and single cell sus-
pensions were plated in a standard tissue culture 24 well-
plates at a density of 40000 cells/well, and then cultured
overnight in a 37°C incubator with 5% CO2. The
pGL4.17-HES1 plasmid bears the -194 to +160 promoter
fragment of the human HES1 gene in the MCS of
pGL4.17[luc2/Neo] vector (Promega, p/n E6721). The
fragment was excised from a pGL2 basic-HES1 plasmid
[64] generously provided by Ndiaye Delphine (Pasteur
Institute, France). pBOS-NICD, a plasmid encoding the
Notch intracellular domain (NICD), was a gift from
Gerry Weinmaster (UCLA, USA). pGL4-75 (hRluc/
CMV) (Promega, p/n E6931) expresses Renilla luciferase
gene under the control of the CMV promoter. Plasmids
were transiently transfected using Fugene 6 (Roche, p/n
11 815 091 001) following manufacturer's instructions.
Two hundred ng of pGL4- and 50 ng of pBOS-NICD and
control pGL4-76 were used in each reaction. All assays
were performed in triplicate. After 24 h of incubation the
cells were lysed and the lysate was transferred to a 96 well
plate. Reporter protein activity was measured in an Infi-
nite 2000® Series plate reader (Tecan) using the Dual-Glo®
Luciferase Assay (Promega, p/n E2920) following manu-
facturer's protocol.
Additional material
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Transcription Factor.
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ties assessed at 10 days in culture.C. Kapplan-Meier survival curves of NOD/
SCID mice xenograft experiments injecting parental PCSCs. 100, 1000, 
10000 and 300000 cells of PCSC-1, PCSC-2 or PCSC-3 were used per injec-
tion as described in Materials and Methods.
Additional file 2 qRT-PCR validation of selected genes. Stem cell mark-
ers in LNCaP (A) and PCSCs (B) and the 66 gene signature genes (C). The 
data for each gene is the average of at least two biological replicates. Error 
bars represent averaged standard error in the measurements of a given 
gene.
Additional file 3 Most significant (p ≤ E-4) functional categories rep-
resented in the 66 genes PS gene set. The numbers indicate the number 
of genes in each category.
Additional file 4 List of TF binding sites enrichments retrieved from 
MSigDB. Upper chart presents the five PSs that are common to LNCaP and 
PCSCs (≥2-fold change and p ≤ 0.01). Lower chart describes those TF that 
are specific for each type of cell line.
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